Therefore, to get some insight into the potential relevance of CD56 as predictive biomarker for NK-sensitivity in breast cancer, we analyzed its expression status in breast cancer tissues using breast carcinoma microarray, containing 100 cases of invasive ductal carcinoma and 10 adjacent normal breast tissues (Supplementary Fig. 2 and Table 1). This evidence concerns the gene NCAM1 and breast carcinoma.